Business
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., April 22, 2020 /PRNewswire/ -- RGX-314 continues to be well-tolerated at all dose levels Long-term, durable treatment effect demonstrated over
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., April 22, 2020 /PRNewswire/ -- \nRGX-314 continues to be well-tolerated at all dose levels Long-term, durable treatment effect demonstrated over two years in Cohort 3 Mean improvement in vision (+14 letters) and stable retinal thickness (+2 µm) 50% of patients (3/6) remain anti-VEGF injection-free over two years 67% of patients (4/6) are anti-VEGF injection-free from nine months to two years Stable intraocular RGX-314 protein expression over two years 73% of patients (8/11) in Cohort 5 remain anti-VEGF injection-free over nine months Intraocular RGX-314 protein levels at six months demonstrate dose-dependent expression across cohorts Company on track to provide one-year data from Cohorts 4 & 5 in mid-2020 and initiate RGX-314 subretinal delivery pivotal program in 2H 2020 Webcast conference call to be hosted Wednesday, April 22 at 8:30 a.m. ET featuring wet AMD Key Opinion Leaders, Allen C. Ho, M.D., Robert Avery, M.D., and Peter Campochiaro, M.D.REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today provided additional long-term data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). \n\"I am impressed by the overall outcomes in patients after a one-time administration of RGX-314. I believe that RGX-314 is the leading gene therapy program for a major retinal disease such as wet AMD and could be an important potential one-time treatment option for AMD patients who require frequent and burdensome anti-VEGF injections. Real-world evidence demonstrates that patients lose vision over time with our current standard of care and incur significant treatment burden with frequent clinic visits and injections,\" said Allen C. Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina and investigator surgeon in the RGX-314 trial. \n\"The clinical profile of RGX-314 appears very promising as a one-time treatment strategy for wet AMD as we continue to learn about the consistent and durable effects of our anti-VEGF gene therapy,\" added Steve Pakola, M.D., Chief Medical Officer of REGENXBIO. \"We are encouraged that all patients in Cohort 5 who were anti-VEGF injection-free at six months re...